Recro Pharma, Inc. provided earnings guidance for the full year 2021. The company is increasing its revenue guidance for the full year 2021 to be in a range of $74 to $76 million, with an EBITDA, as adjusted target range of $16 to $18 million and a net loss range of $11.6 to $13.6 million.